Covid-19 Vaccine Takes at least One Year to be Validated

American company developed a potential vaccine in 42 days, but product still needs to be validated.

Although scientists have already sequenced the genome of the new coronavirus and even cultured the organism in the laboratory, the full development of a vaccine against Covid-19 should still take at least a year, according to an estimate made by Anthony Fauci, head of the National Institutes of Health. US Allergy and Infectious Diseases.

Last week, at a meeting between biotechnology companies and the United States government, Moderna Pharmaceuticals CEO Stephane Bancel told President Donald Trump that his company has already delivered a possible vaccine for testing by the country’s Department of Health.

The news cheered the chief executive. However, questioned by other participants, Bacel considered that the compound will be available at least a year and a half from now – if the vaccine is approved.

After all, before it is applied to patients, the product developed must undergo rigorous experiments that prove whether the substance is effective and does not pose risks to human health.

According to the Technology Review website, only the security tests last three months. Thereafter, the vaccine is applied to hundreds or thousands of people in regions affected by the epidemic in order to see if they will be immunized. This usually takes a year, regardless of the vaccine technology used.

Moderna develops gene vaccines, also known as mRNA. To produce them, the researchers first analyze the components of the virus and develop a genetic instruction to block its action. Then they inject the solution into a nanoparticle, which is then introduced into a person.

In the case of the new coronavirus, the company added genetic instructions to block the spiny protein used by the virus to infect and invade human cells. In this way, the patient’s body could be immunized.

“Conventional” vaccines, on the other hand, carry copies of attenuated viruses, which when administered to the human body induce the production of antibodies against the disease.

According to the Korea Pharmaceutical Bio Association, also 15 pharmaceutical bio-industries have begun to develop corona vaccines and treatments, and four government agencies have entered R & D.

In the case of preventive vaccines, R & D is being carried out around companies with existing flu vaccine development capabilities such as GC Green Cross and SK Bioscience. They have the capacity to produce their own vaccines, so if they are successful in developing vaccines, they will be able to supply domestically.

SK Bioscience supported the development and evaluation of new coronavirus immunogens in the 2019 Korea Centers for Disease Control and Development, and plans to promote vaccine production, supply, and commercialization through consultation with relevant organizations at home and abroad.
In the case of Green Cross, both vaccines and therapeutics will be researched and developed, thus supporting the development of Zylbon’s synthetic antigen-based corona19 subunit vaccine candidates and the discovery of monoclonal antibody nonclinical candidates for the treatment of new swine coronavirus in 2019.

Sumagen has begun developing corona 19 vaccines through a research service contract with the International Vaccine Research Institute, and plans to develop vaccines containing gene core antigens through platform technology that can be commonly applied to various virus-derived infectious diseases.

In addition, Boryeong Bio Pharma is preparing to develop a vaccine, and in the case of G-Plus Life Sciences, the vaccine will be developed through a plant-based platform.

In the case of therapeutics, the development will be conducted either by finding new candidates to treat Corona 19 or by verifying the efficacy of Corona 19 in existing drugs.
 

Celltrion has supported the discovery of nonclinical candidates for monoclonal antibodies for the treatment of new swine coronaviruses in 2019.

Korea United Pharmaceutical is planning to conduct phase 1 clinical trials to inhibit the progression of severe pneumonia with inhaled steroids that have chronic airway inflammation. After the development, it will apply for approval for therapeutic purposes.

Sellive is communicating with a number of Chinese pharmaceutical companies, including Fast Track, as it is known that iCP-NI is a treatment for severe sepsis.

Novacel Technology signed a memorandum of understanding with AD Korea for research and development of Corona 19 Therapies, and Immed Med will begin Phase 2 clinical trial for the treatment of Corona 19 with HzVSFv13.

In addition, Utileex has begun to develop new drugs for the treatment of corona19 using immuno-antibodies, and Genomic Tree has begun developing molecular diagnostic kits and antiviral therapies with Chungnam University. Kynosmed will verify its antiviral efficacy through its own research compound similar to Remdesivir and will screen for the creation of new drugs with the Institute of Pasteur Korea.

On the other hand, public-private cooperation models, in which domestic government agencies, research institutes, and pharmaceutical companies are gathering power to develop vaccines and treatments, are also being activated.

The National Institutes of Health has recently announced eight research projects for the development of rapid diagnostics, vaccines, and treatments necessary for quarantine.

It is expected that such public-private cooperation will speed up the development speed in terms of regulations such as technical aspects and permits, as it is difficult to develop vaccines and treatments in a short time.

In addition, the association said, “In addition, we should benchmark overseas cases with active public-private cooperation, such as the European Innovative Drug Initiative (IMI) and the National Institutes of Health’s AMP.”

In addition, the CEPI, an international non-profit organization, is supporting four Corona19 projects around the world with support from governments, including the Bill Gate Foundation.

Although R & D projects related to Corona 19 are being actively implemented in Korea, it is pointed out that bold government support and public-private cooperation system are needed to improve the effectiveness of the project.

 

Reviewer overview

Covid-19 Vaccine Takes at least One Year to be Validated - /10

Summary

American company developed a potential vaccine in 42 days, but product still needs to be validated.

0 Bad!